
    
      Following screening, baseline measurements and informed consent, patients will receive
      BXT-51072 40 mg or placebo in a 2:1 ratio, 30 minutes before their scheduled PCI and then
      three times per day for 2 days. There will be 5 treatment visits and 3 follow-up visits.

      Blood samples will be obtained for CK-MB, troponin and routine chemistry. A 24-hour
      continuous electrocardiogram will be obtained following the PCI and regular
      electrocardiograms will be obtained during the study and follow-up period.
    
  